The clinical use of autologous marrow transplantation in acute myeloid leukemia (AML) has been hampered by the inability to collect adequate numbers of cells after remission induction chemotherapy and the notably delayed hematopoietic regeneration following autograft reinfusion. Here we present a study in which the feasibility of mobilizing stem cells was investigated in newly diagnosed AML. 
High dose chemotherapy followed by autologous bone marrow transplantation (ABMT) is commonly applied as a post remission treatment modality in patients with acute myeloid leukemia (AML) as an alternative of allogeneic marrow transplantation. The results are comparable to those seen after HLA-matched allotransplantation. 1 One of the major limitations of the applicability of ABMT is that a considerable proportion of patients who have entered complete remission have no access to transplantation in clinical practice. These candidates have to be withdrawn from ABMT prematurely for several reasons, eg the collection of an insufficient autograft or the hazards of a prolonged period of cytopenia, a consequence of the slow hematological regeneration typical of ABMT in AML. [1] [2] [3] [4] [5] The role of autologous stem cell transplantation in AML would potentially be greatly advanced if the repopulation abilities of the grafts were more potent. One possibility for overcoming these limitations is the use of peripheral blood autografts, which might be easier to collect and which might also have a better potential for hematopoietic repopulation. In fact, in patients with non-myeloid hematological malignancies, peripheral blood stem cell transplantation (PBSCT) has been shown to permit early hematopoietic reconstitution. 6 However, as yet, these observations have mainly been based on experiences in patients with solid tumors and lymphoid malignancies who receive a significantly less aggressive treatment than do patients with AML. In addition, residual normal hematopoietic stem cell function in patients with AML may not be intact. 7 We set out to evaluate the feasibility of collecting peripheral blood stem cells in newly diagnosed patients with AML. These patients were submitted to two cycles of remission induction therapy after which an attempt was made to collect peripheral blood stem cells with varying mobilization regimens of G-CSF.
Materials and methods
This was a combined study of the Dutch-Belgian HematoOncology Cooperative Group HOVON and the Swiss Cancer Group SAKK in which the feasibility of collecting per-ipheral stem cells was investigated in a pilot study. Ninetysix patients (49% males) with previously untreated AML were prospectively entered at age 17-65 years (mean 45 years). AML was diagnosed and classified according to the French-American-British (FAB) classification. 8 Patients planned for autografting were scheduled for peripheral blood stem cell mobilization.
Peripheral blood stem cell mobilization
To study the feasibility of G-CSF to mobilize peripheral stem cells in AML, a first series of patients (n = 31) were mobilized with a low dose regimen. However, in view of the high failure rate and long durations of mobilization this scheme was empirically modified in three successive steps in an effort to improve the outcome of collecting peripheral stem cells. At the end of this study four different schedules of G-CSF administration were used. (1) low dose G-CSF: G-CSF was started immediately after the second chemotherapy course at a dose of 150 g/m 2 s.c. and continued until completion of pheresis (n = 31), but no more than 40 days; (2) low dose + boost G-CSF: G-CSF was given exactly as in (1), but when granulocytes rose to 0.2 × 10 9 /l or more, the dose was escalated to 600 g/m 2 s.c. and continued until completion of pheresis (n = 7); (3) 450 G-CSF: G-CSF was applied at a dose of 450 g/m 2 s.c. beginning only at the point of granulocytes recovery (0.2 × 10 9 /l) or the appearance of detectable numbers of CD34 + cells in the blood (n = 13); (4) 600 G-CSF: as schedule 3, but G-CSF was applied at a dose of 600 g/m 2 (n = 12). Leukapheresis was started when leukocytes had risen to 2 × 10 9 /l and it was continued on subsequent days with the objective of collecting a minimum of 1 × 10 8 /kg nucleated cells or 2 × 10 6 /kg CD34 + cells. The number of CD34 + cells was assessed by flow cytometry and the number of colony-forming unit granulocyte-macrophage (CFU-GM) was measured in in vitro colony assays. Leukapheresis products were cryopreserved for later use. G-CSF mobilization was discontinued prematurely in case of evidence of progressive leukemia or persisting AML on marrow evaluation. In the analysis of stem cell collection, the results of the low dose mobilization schedule 1 were compared to the combined results of schedules 2, 3 and 4. Hematological recovery following re-infusion of PBSC was evaluated in comparison to the ABMT cases from the HOVON-4/4A study, the previous collaborative study of the HOVON and SAKK groups in adults with AML. 2 
Peripheral blood stem cell transplantation
Peripheral blood stem cell transplantation was given to a limited number of patients following conditioning with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). The results were compared with a group of patients transplanted with autologous bone marrow cells.
Statistical analysis
Wilcoxon's rank sum test was applied to test for differences in harvest between patients mobilized with low and high dose G-CSF, and between PBSC harvest and bone marrow harvest. Median time to recovery after transplantation was calculated by the actuarial method of Kaplan and Meier. Patients who did not recover were censored at date of last contact or death. The log rank test was applied to test for differences in recovery between patients transplanted with autologous bone marrow and patients with peripheral blood stem cells.
Results
The feasibility of collecting peripheral blood stem cells was studied in 96 patients with AML The characteristics of the population studied are given in Table 1 with regard to age, FAB classification and karyotyping. Of 96 evaluable cases, 76 patients (79%) attained a CR. Mobilization with G-CSF was not undertaken in 33 patients, in most cases because of early treatment failure (toxic death or progressive leukemia and the inability to continue on protocol (n = 24)). Refusals (n = 5), immediate allogeneic or ABMT (n = 4) 3 and 4) . Inability of pheresis was due to the lack of a rise of circulating CD34 + cells (n = 3) or the decision to perform an allogeneic BMT (n = 3) or other reasons. The median number of phereses conducted was three per patient for low (1) and high (2, 3, 4) G-CSF schedules. G-CSF treatment was started after a median of 22 days (range 11-39) in groups 3 and 4. The cell yields were significantly higher for the high dose G-CSF regimens. In patients on G-CSF schedule 1 (150 g/m 2 ), the median yields were 2.0 × 10 6 /kg CD34 + cells. In patients on G-CSF schedules 2, 3 and 4, the harvests contained a median 3.6 × 10 6 /kg CD34 + cells ( Table 2 ). The number of CD34 + cells per individual group were: 2, 3.0 (0.1-5.5), median (range); n = 7; 3 5.0 (0.0-60.3), n = 11; 4, 3.2 (0.0-43.6), n = 12. In fact in only 46% of the patients on the low dose schedule 1, the required minimum number of 2 × 10 6 /kg CD34 + cells could be obtained, whereas the target number of 2 × 10 6
CD34
+ cells or more was successfully obtained in 79% of cases on schedules 2, 3 and 4 (P = 0.01).
Recovery following PBSCT in comparison to ABMT
Twenty-eight patients received the PBSC autograft following busulfan-cyclophosphamide conditioning. The median number of days to recover neutrophils (у0.5 × 10 9 /l) was 17 (range 9-160) and platelets (towards 20 × 10 9 /l) was 26 (range 4-428). There was a distinct correlation between the number of CD34 + cells/kg in the graft and the time of recovery. When the number of CD34 + cells was subdivided /l G-CSF was given at a dose of 600 g/m 2 ; 3, G-CSF (450 g/m 2 ) was given when the granulocytes recovered to 0.2 × 10 9 /l; 4, similar to 3 except the dose of G-CSF (600 g/m 2 ). *P = 0.21; **P = 0.05 in three classes (1.1-2.9 CD34 + /kg, n = 8; 3-12.1 CD34 + /kg, n = 9 and 12.1-65.9 CD34 + /kg, n = 9) a significantly faster recovery was observed in the third group compared to the first group with regard to granulocyte Ͼ0.5 × 10 9 /l (median 14 vs 19 days respectively, P = 0.04, test for trend) and platelets Ͼ20 × 10 9 /l (median 11 vs 55 days respectively, P = 0.001, test for trend). This association is not apparent with regard to the relation between numbers of CFU-GM or mononuclear cells in the graft and the time to recovery. The results were also compared to ABMT results of the HOVON-SAKK HOVON4/4A study that had almost employed the same chemotherapy except for the use of daunomycin (45 mg/m 2 ) instead of idarubicin in cycle 1 and a third chemotherapy course before ABMT. 9 In 41 ABMT cases, a significantly lower number of mononuclear cells and CFU-GM were infused compared to PBSCT (Table 3a) . The median numbers of days to neutrophil and platelet recovery were significantly prolonged in the ABMT group compared to the PBSCT group, ie 37 days and 96 days, respectively compared to the PBSCT group (Table 3) .
Discussion
The value of autologous stem cell transplantation in the treatment of patients with AML in first CR is still the subject of intensive investigation. 1 First of all, various approaches of dose-intensified treatment based either on allogeneic stem cell transplantation, autologous marrow transplantation or seqential cycles of high dose chemotherapy without stem cell support have produced roughly similar overall survival results. 4, 5, [10] [11] [12] Second, based on The results of hematological recovery of 27 patients in first CR transplanted with PBSCT (this study) were compared to the results of hematological recovery after ABMT in 41 patients in the previous HOVON-SAKK AML study (HOVON4-trial). ANC = absolute neutrophil count; PLT = platelets.
retrospective analysis there is a growing awareness that good risk patients, ie individuals with a relatively low probability of relapse following CR, may not need aggressive post-remission therapy in first CR since the risks of this procedure may not outweigh the benefits. Third, at present, allogeneic BMT and ABMT probably offer the best antileukemic treatment as evidenced by significantly reduced relapse rates, but they do not necessarily provide better survival rates because of a higher mortality. 4, 5 The toxic mortality associated with ABMT is especially linked to the slow hematopoietic regeneration that is characteristic of this type of transplantation in patients with AML. Thus, one may assume that the ultimate outcome of ABMT would be improved if hematological recovery could be hastened and, as a result, morbidity and mortality due to infections and hemorrhagic complications reduced. The use of PBSCT, instead of AMBT, might be attractive in that it might permit faster hematopoietic recovery. 6 In any case, in patients with malignancies other than AML, PBSCT has provided more rapid hematopoietic reconstitution in comparison to autologous marrow grafts. In addition, PBSCT, as an alternative source of stem cells, might also have the advantage of a more successful harvest of an appropriate size graft. Frequently it has appeared impossible to aspirate sufficient numbers of marrow cells to allow for transplantation which limits the number of patients scheduled for ABMT. 2 The results of the feasibility study presented here support the notion that PBSC may be a better alternative to autologous bone marrow. It is evident from these results that in the majority of cases an adequate PBSC graft can be obtained following aggressive chemotherapy and appropriate G-CSF mobilization. This objective is achieved in most patients with no more than three leukaphereses. It is also clear from our analysis that the G-CSF mobilization schedule has a significant impact on the yield, as suggested by Demirer et al 13 in a small pilot study. The three higher dose G-CSF schedules produced considerably higher yields. As a matter of fact, the regimens that employed G-CSF at 450 g/m 2 or 600 g/m 2 from the earliest signs of recovery (at the point of granulocyte regeneration of 0.2 × 10 9 /l or the appearance of circulating CD34 + cells) permitted a successful harvest of more than 2.0 × 10 6 CD34 + cells in 79% of cases and a median total yield of 3.6 × 10 6 /kg CD34 + cells per patient. These numbers also appear to exceed the numbers presented in a recent study by Jowitt et al 14 where a third of the patients failed to yield a PBSC harvest above the minimum threshold of 5 × 10 4 CFU-GM/kg. The results of this study also show a rapid neutrophil and platelet recovery following reinfusion of PBSC after marrow ablative therapy that is unusual for autografting patients with AML. Within approximately 2 weeks, neutrophil and platelets begin to recover. The faster recovery after PBSCT might be due to the infusion of a larger number of CD34 + stem cells. This might have the disadvantage that a larger number of residual malignant stem cells are also infused in the patient resulting in a higher risk of leukemic relapse. However, the data of this pilot study do not support this contention so far since the overall survival was comparable to ABMT. A greater number of patients in prospective randomized studies and with sufficient length of follow-up will be needed to settle this issue definitively. Taken together, the data in this study indicate a number of potential advantages of PBSCT over ABMT that may lead to an easier applicability in clinical practice, a greater availability to patients and perhaps better survival outcome in the end. Hence, these data warrant future prospective studies to critically evaluate the role of PBSCT in the treatment of patients with AML and to establish whether the promise of PBSCT autografts translates into real clinical benefits.
